Seattle stem cell startup lands $10M to speed development of its drug discovery platforms – Puget Sound Business Journal (Seattle)

Seattle startup Curi Bio Inc. has closed a $10 million Series A round, the company said Wednesday.
Curi Bio back in March announced it was raising a $6 million Series A, but ended up surpassing that as investors provided the startup with funds beyond what it originally asked for.
Investors UTC Investment and DS Asset Management joined Dynamk Capital, the original lead for the round, reaching $10 million total. To date, the startup has raised $21 million, including both dilutive and nondilutive funds.
“This funding validates the need for more predictive and mature human stem cell platforms to close the gap between preclinical results and clinical outcomes,” Curi Bio CEO Michael Cho said a March release announcing the first portion of the funding. Cho is a licensed patent attorney, and his background is in law and business management, according to his LinkedIn page.
The startup develops stem cell-based platforms for drug discovery using human cells, biosystems and data analysis. It aims to close the gap between the results of preclinical studies and what actually happens in a clinical setting.
Curi Bio plans to use the funding to grow its business and speed up development of its platforms, according to the release.
“Curi Bio’s technology platforms create significant value for pharma and biotech companies by accelerating discovery timelines and increasing the chances of success for new therapies in development,” Dynamk Capital Managing Partner Gustavo Mahler said in the release.
Mahler joined Curi Bio’s board following Dynamk Capital’s investment, according to the March news release. He joined Dynamk in 2019 after more than 10 years at Bothell biotech AGC Biologics, including as CEO from December 2015 to April 2019, according to his LinkedIn and Dynamk staff pages.
In October, Curi Bio partnered with Seoul-based stem cell technology company Nexel on a joint venture company called Celogics to develop and commercialize other stem cell products for drug discovery, safety testing and research. Celogics is also based in Seattle.
Want to stay ahead of who & what is next? Sent weekly, the Beat is your definitive look at Seattle’s innovation economy, offering news, analysis & more on the people, companies & ideas driving your region forward. Follow the Beat.

source

Share:

More Posts

Market Research

Pulse Surveys

Turn feedback into action

Our survey platform makes it easy to measure and understand feedback so you can drive growth and innovation

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

Pulse LS

Pulse LS

Use a managed Limesurvey and our expertise for creating complex forms and token based user management. Use optional mailing system to send survey invitation to each participant and track progress of the response status. Industry standard SPSS / R output supported